Article

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine

2022-04-15

Abstract excerpt

<title>Abstract</title> <p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants have caused multiple waves of infection globally. This phase 2/3 study evaluated the safety and immunogenicity of the bivalent vaccine candidate mRNA-1273.211 (equal mRNA amounts of ancestral SARS-CoV-2 and Beta variant spike proteins) as 50-µg (n=300) and 100-µg (n=595) first booster doses approximately 8.8-9.8 month...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9653807f-dcca-5f31-a647-86956f39883d
DOI: 10.21203/rs.3.rs-1555201/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineDOI 10.21203/rs.3.rs-1555201/v1Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19Semantic proximity Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity Read

Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersSemantic proximity Read

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman PrimatesSemantic proximity Read

Immunogenicity of the BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity Read

Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccineSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read